
I Tried Full-Body Deodorant—Here's The Good, Bad, & The Sweaty
As beauty editors, we always keep our ears to the ground when it comes to product trends and new launches. I'm not just talking about what hits our inboxes and desks on a daily basis, but also out in the wild: When I'm at the pharmacy, the grocery store, or wandering the aisles at Sephora — I truly live and breathe the stuff. Which brings me to recently, when a Jerry Seinfeld-esque internal monologue wondered, 'What's the deal with full-body deodorant?'
All of a sudden, they were everywhere. Claims like '72-hour odor control' (pretty sure showering regularly has this part covered?) and H2T protection seemed too good to be true. I knew I had to dig deeper.
'People sweat everywhere, not just the underarms,' explains New York-based dermatologist Shereene Idriss, M.D. 'The rise of 'whole body' formulas is a response to the fact that people are becoming more aware — and frankly, more self-conscious — about odor and sweating in other areas like the chest, back, feet, and yes, even the butt crack.' As far as sweaty spots go, I deal with boob and back sweat during the summer. But normally, I'd either just ignore it or hit my cleavage with a blast of my Dove antiperspirant; after all, it's more or less the same stuff…right?
According to Dr. Idriss, not necessarily: 'Formula-wise, yes, there can be differences,' she says. 'Whole body deodorants tend to be formulated with gentler, odor-neutralizing ingredients like baking soda, magnesium hydroxide, or even probiotic blends rather than the heavy-duty aluminum-based antiperspirants you'd find in clinical strength underarm products.' Sure enough, a closer look at product labels revealed ingredients like tapioca starch, coconut oil, and even niacinamide, which work to balance skin and absorb oil where needed.
So far, I was on board. However, during my research, I couldn't help but notice cheeky advertisements that not-so-subtly seemed to prey on women's shame around vaginal odor. This was problematic at best, and a health risk at worst. 'My concern with patients using whole body deodorants in the groin is that they could get into the vagina if patients do not use them sparingly, and these products could be irritating to delicate tissue,' says New York based-OB/GYN Isabel Blumberg, M.D. 'If a smell seems concerning, then a woman should see her doctor as that could be a sign of something clinical like a bacterial infection.' Her best course of action? Opt for underwear made from breathable fabrics and if needed, a liner to help keep things comfortable. 'Pads and liners, like ones from Carefree, are specifically designed for the genital region and are easy to change or swap out to keep you feeling fresh and clean,' she explains.
But perhaps most exciting (at least for those who only had 'powder fresh' or vague floral scent options to choose from growing up in the 2000s), whole body deos seem to serve double duty as both anti-B.O. protection and wearable fragrance these days. Dove's Sage & Lavender Cooling Whole Body Deo and Native's Sea Salt & Cedar Whole Body were among my most reached for, as was Curie's Santal Sage, which I would readily buy as an eau de parfum. Meanwhile, Daise dreams up deodorant (and corresponding body mists) in creative scent combos like Pear & Patchouli and Raspberry & Mint. (Not to mention, the tie-dye-inspired packaging brightens up any bathroom counter.)
So, where's a sweaty gal to go from here? I give whole body deodorants a green flag when it comes to refreshing underarms, chest, and back — especially during the day. That said, I'd love to see brands stop encouraging (subtly or otherwise) to use the stuff on the crotch. Below, a real-deal overview of the best ones I tried.
Dove Whole Body Deodorant, $11.99
Pros: Smells great, instant refreshing feeling
Cons: None!
I've been on the natural deo train for years now, but on days when I have a grueling workout class and don't want to worry about B.O. ruining the vibe, I'll use Dove's regular deodorant spray. To stress test the whole body version, I swapped this one in for my hot yoga classes and nearly couldn't tell the difference. It performs surprisingly well for an aluminum-free spray, and the Sage & Lavender scent was my favorite among all the deodorants I tested. The price is right, and it felt cooling and refreshing when I needed it most.
Native Sensitive Whole Body Deodorant Stick, $14 & Whole Body Deodorant Spray, $14
Pros: Felt and worked most like my normal deodorant
Cons: Minor issues with the spray nozzle
Along with Dove's spray, Native's OG stick is my daily deo of choice, and I have to say, I was super impressed with both the stick and spray versions of the brand's whole body deodorant. The scent options are elevated, and the stuff just plain works. I brought the Vanilla & Raspberry Whole Body Spray on a recent trip to Morocco, and it kept me feeling fresh and non-stinky during the hottest days in Marrakech. It's a yes from me!
Daise All Body Spray & Deodorant, $5.99
Pros: Unique scents, great packaging, very affordable
Cons: Doesn't last as long as I'd like
I really, really wanted to love this one, but I had some issues with Daise's All Body Spray & Deodorant. The scents and packaging are an 11/10, but as someone who lives in a hot climate and works out a lot, this just didn't last as long as I needed it to. That said, I think the accessible price point (in most cases, less than half of competitors') and the matching body sprays are a smart concept. And hey, this might work for you if you're not as sweaty as I am — and I love that for you! As for me? If the brand ever chooses to make an extra-strength formula, I will be the first in line to buy.
Curie Deodorant & Body Spray, $16
Pros: Gentle on skin, travel-friendly size, non-aerosol
Cons: A little pricey
I've tried Curie's stick deodorant before and loved it, so I had high expectations for the spray. Right off the bat, I liked that the size was purse- and gym bag-friendly since I like to reapply during the day as needed. Second, this was the only non-aerosol spray I tried, which — depending on where you live — makes the empty bottle easier to recycle. I was pretty impressed with its performance (I didn't notice any stinky pits during testing), but if you really like that dry-touch feeling from your deodorant, this one doesn't deliver that as effectively as some others I tried. But if you don't mind a little (not a lot) moisture — and reminder, none of these are labeled as antiperspirants, and none contain aluminum — then by all means, party on.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
AESTURA, Korea's #1 Dermatologist-Recommended Dermocosmetic Brand Launches Exclusively at Sephora Australia
Premium dermocosmetic brand specialising in sensitive skin launches from August 26th, bringing clinically-proven innovation to Australian skincare market SYDNEY, July 28, 2025 /PRNewswire/ -- AESTURA, Korea's #1 dermatologist-recommended dermocosmetic brand for sensitive skin[1], breaks new ground in the Australian skincare market with its exclusive launch at Sephora Australia stores and on beginning August 26th, 2025. This strategic partnership with Sephora Australia answers the growing demand for advanced, science-backed solutions in the dermatologist skincare category. AESTURA is more than just a skincare brand. It is the culmination of over 40 years of scientific research and dermatological expertise. AESTURA's specialised sensitive skin solutions are trusted by dermatologists at Korea's leading medical institutions. The brand has been ranked as the No. 1 cosmetic brand sold in skin clinics for 9 consecutive years[2], and has widespread distribution, reaching 100% of tertiary general hospitals in South Korea[3]. "We are thrilled to introduce AESTURA to our Australian beauty community," says Sheila Dam, Brand General Manager at AESTURA. "Our products and formulas have been trusted by Korean dermatologists and sensitive-skin users alike for decades, and now, with this launch at Sephora Australia, we are excited to share these innovative sensitive-skin solutions to a wider audience." AESTURA's innovative skincare harnesses patented Triple-Lipid Technology™, featuring one million ceramide capsules in every bottle engineered to mimic the skin's natural structure and target the fundamental pillars of skin health: hydration, protection, and restoration. The ATOBARRIER365 Collection: Hero Products for Sensitive Skin At the heart of AESTURA's breakthrough skincare is the ATOBARRIER365 Collection, featuring the viral sensation ATOBARRIER365 Cream. The hero product has become a phenomenon in Korea, with one cream sold every 7 seconds[6] due to its proven ability to strengthen, protect and hydrate the skin. The ATOBARRIER365 Cream features patented technology with one million capsules packed with ceramides in every bottle[4]. These capsules stay on the skin for up to 18 hours[5], delivering hydration while strengthening, repairing, and protecting the moisture barrier which can be weakened in sensitive skin. "Sensitive skin often struggles with compromised skin barrier, making it more susceptible to dryness and irritation," says Dr. Richard D. Granstein, an academic dermatologist and Chair of AESTURA's Derma-Science Advisory Board. Additionally, according to Dr. Y. Claire Chang, board-certified dermatologist at UnionDerm and clinical instructor at Mount Sinai Hospital, "For those with sensitive skin, ceramides are crucial. It's not just about any ceramides, though. Sensitive skin benefits most from specific ceramides that mimic those naturally found in the skin. AESTURA's innovative capsule technology, used in the ATOBARRIER365 Cream, encapsulates these barrier-boosting ceramides, allowing for deeper penetration to help rebuild and strengthen the skin's natural barrier. Results reported from a clinical trial of the ATOBARRIER365 Cream demonstrated significantly enhanced skin hydration and improved barrier function." The complete ATOBARRIER365 Collection includes products formulated to address specific skin concerns like dryness, irritation, and barrier damage while enhancing overall skin health. Each product is designed for daily use, providing a complete routine specifically developed for sensitive skin needs. Exclusive Launch at Sephora Australia The exclusive partnership with Sephora Australia underscores both brands' commitment to offering premium, results-driven skincare solutions. Sephora's reputation for curating the world's most coveted beauty brands makes it the ideal retail partner for AESTURA's Australian debut. "Sephora Australia is excited to exclusively launch AESTURA, bringing our clients access to Korea's most trusted dermocosmetic brand," says Mark O'Keefe, Country Manager Sephora ANZ. "Our clients value effective, results-driven skincare, and AESTURA delivers on this by offering cutting-edge solutions specifically designed for sensitive skin that support barrier health. We look forward to introducing AESTURA to our Sephora community and know that it will be a valuable addition to our assortment." Market Impact and Availability The Australian launch comes at a time when consumer interest in K-beauty and dermocosmetic products continues to grow, with Australian consumers increasingly seeking scientifically-backed skincare solutions and prioritising genuine skin health over trend-driven routines. Australia's harsh environmental factors - from intense UV exposure to dramatic seasonal transitions - demand skincare solutions of exceptional calibre. AESTURA's arrival fills a crucial gap in the market for dermatologist-recommended brand that combine Korean innovation with clinical credibility. Starting August 26th, AESTURA products will be available at all Sephora Australia and New Zealand stores nationwide and through Sephora's online platform, ensuring accessibility for customers across the country. [1]Based on research conducted by Kantar with dermatologists in South Korea, 2023. [2]Korea Consumer Agency, 2016-2024, Best Brand Award of the Year in the category of cosmetic brands sold in skin clinics. [3]Distribution Partners Based on Health Insurance Review & Assessment Service (HIRA) Statistical Figures [4]80mL/2.7 fl. oz. [5]Ex-vivo test on human skin [6]3M Units Sales: 2018.09 ~ 2024.01 cumulative unit sales1 sold every 7 seconds : 2024.01 unit sales About AESTURA AESTURA is Korea's #1 dermatologist-recommended dermocosmetic brand, dedicated to developing scientifically-proven skincare solutions that bridge the gap between cosmetics and dermatological care. Founded on the principle of combining advanced research with gentle effectiveness, AESTURA has earned the trust of Korean dermatologists and consumers alike. The brand's commitment to clinical excellence and innovation has made it a leader in the Korean beauty industry and a sought-after name in global skincare markets. For more information about AESTURA, visit View original content to download multimedia: SOURCE AESTURA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille


Time Business News
18 hours ago
- Time Business News
BrainSim-X Launches Developer Platform for Neural Simulation Data
BrainSim-X announced the launch of a developer access program that allows researchers and app developers to integrate brain simulation data into their applications. More information about the platform is available at their official website . The Bangalore-based research initiative said the platform will focus on medical applications, particularly epilepsy research and neurological treatment development. Unlike typical API services, BrainSim-X requires developers to submit applications explaining their intended use cases before gaining access to the platform. Interested developers can request API credentials through their secure portal. The approval process takes approximately one week, with the organization reviewing each application to ensure it aligns with their medical research focus. One developer who has used the platform for three months described it as providing detailed neural activity data that requires significant technical expertise to implement properly. A detailed account of this developer's experience can be found in their comprehensive review . 'The platform generates large amounts of data that require powerful computing resources,' the developer said. 'It's designed for serious medical research rather than general app development.' The organization provides documentation and support for developers working on brain-computer interfaces, neuroscience research projects, and medical applications. Their research findings are available for review in published papers. Real-time data access became available recently, allowing developers to integrate live neural simulation feeds into their applications. The platform is intended for researchers studying brain activity patterns, testing neurological treatments, and developing diagnostic tools. BrainSim-X operates the service through a secure API that provides access to neural simulation data generated by their brain modeling platform. Technical requirements include high-memory computing systems capable of processing large neural datasets. Additional technical insights about the platform's capabilities can be found in this technical analysis . The research initiative says the developer program represents part of their commitment to making brain simulation technology accessible to the global research community. Applications are evaluated based on their potential contribution to medical research and neurological treatment development. BrainSim-X has not disclosed revenue generated from the developer platform, stating that funds support ongoing research activities. The organization expects demand for the platform to grow as more researchers learn about neural simulation applications in medical research. Future platform updates will include enhanced simulation capabilities and additional tools for analyzing neural activity patterns. BrainSim-X says the developer program differentiates it from commercial AI companies by focusing on open research collaboration rather than proprietary technology development. The platform supports research into cognitive enhancement, educational technology, and advanced diagnostic systems. Developers interested in accessing the platform must demonstrate relevant research experience and explain how they plan to use neural simulation data in their projects. BrainSim-X provides training resources to help developers understand neuroscience concepts necessary for effectively using the platform. The organization says it will continue expanding the developer program while maintaining focus on medical and scientific applications. Related Resources TIME BUSINESS NEWS